Back to search

University of Patras

Ρύθμιση βιοσύνθεσης υαλουρονικού οξέος σε κυτταρικά μοντέλα καρκίνου του μαστού

Abstract

dc:description

Breast cancer is one of the most common types of cancer occurring in women. It is a highly heterogeneous disease and, for thereapeutical reasons, is classified as –estrogen-dependent or -independent breast cancer. One of the most important clinical markers for breast cancer classification is the estrogen receptor α (ERα). Importantly, about 70% of breast cancers are diagnosed as ERα+ and exhibit better patient outcome than ERα- tumors, which exhibit high incidence of metastases and poor patient outcomes. Under pathological conditions, such as cancer, an extended remodeling of the extracellular matrix (ECM) occurs within tissues. An important constituent of the ECM is the linear heteropolysaccharide hyaluronan, which is synthesized by transmembrane enzymes termed hyaluronan synthases (HASes). High concentrations of hyaluronan are correlated with higher incidence of metastasis and poor outcome of patients with breast cancer. Hyaluronan interacts with its cellular receptors, mainly CD44, to regulate almost every aspect of cellular behavior, such as migration, invasion, proliferation, differentiation and metastasis, in breast cancer cells. Given the prominent role of hyaluronan in breast cancer cell biology, this doctorate’s thesis has focused οn the study and characterization of novel hyaluronan biosynthesis inhibitors.4-methyl-umbelliferone (4-MU) is a non-toxic dietary supplement found in plants such as chamomile and has been shown to inhibit hyaluronan production in several cell types. In this doctarate’s study, we hypothesized that estrogen receptor, a major prognostic factor in the clinical evolution and therapeutic management of breast cancer, would provide a differential effect on the biology of breast cancer subtypes vis-à-vis 4-MU treatment. Indeed, 4-MU inhibited hyaluronan production by ERα+ and ERα- breast cancer cells, with a stronger effect being observed in cells lacking ERα expression. Loss of newly synthesized hyaluronan was accompanied by the significant reduction of HAS2 and the hyaluronidases HYAL-1 and HYAL-2 gene expressions. Moreover, 4-MU-treated cells displayed altered cell morphology, accompanied by loss of the hyaluronan receptor CD44 from the cell surface protrusions. Treatment of the cells with 4-MU caused significant reduction in cell proliferation and growth. Different results were observed in the context of cell proliferation between ERα+ and ERα- cells. Specifically, while in ERα+ cells 4-MU induced apoptosis and/or anoikis, in ERα- cells 4-MU likely promoted cell cycle arrest. Furthermore, 4-MU reduced migration and invasion, while upregulated the adhesive potential of breast cancer cells on specific substrates. These observations were accompanied by significant alterations in the expression and activity of specific extracellular matrix-degrading enzymes and pro-inflammatory mediators.Salicylate and acetyl-salicylic acid (aspirin) are widely utilized for many decades as potent anti-inflammatory drugs. In several epidemiological and clinical studies, these compounds displayed significant anti-cancer properties. Nevertheless, the exact underline mechanisms of their anti-cancer action are not yet clarified. This study examined the ability of salicylate -metabolic by-product of aspirin occurring rapidly in vivo by the action of endogenous esterases- to inhibit hyaluronan production by breast cancer cells. Salicylate was found to rapidly activate the kinase AMPK, which is known to phosphorylate and inhibit HAS2, resulting in inhibition of hyaluronan synthesis by metastatic breast cancer cells. Moreover, salicylate reduced HAS2, while upregulated HYAL-2 and CD44. Incubation of breast cancer cells with salicylate caused significant reorganization of the actin cytoskeleton and redistribution of CD44, events that were accompanied by reduction of cell motility. Furthermore, salicylate promoted cell cycle arrest and inhibited cell proliferation. Given the urgent need for discovery of novel and more effective inhibitors of hyaluronan synthases, the ability of a group of compounds to inhibit hyaluronan production was examined. In this study, a new inhibitor of hyaluronan biosynthesis, termed SMD1736, was identified. SMD1736, a thymidine analog, is approximately 12.5-fold more potent from the known inhibitor of hyaluronan synthesis 4-MU. Incubation of metastatic breast cancer cells with SMD1736 significantly affected the expression of hyaluronan related genes (HASes, HYALs, CD44 and RHAMM). The observed reduction of hyaluronan biosynthesis by SMD1736 in breast cancer cells was accompanied by significant inhibition of their aggressive properties. Specifically, SMD1736 reduced cell proliferation, probably through cell cycle arrest. The migratory and invasive potential of breast cancer cells was also reduced by SMD1736, observations that were followed by alterations in the actin cytoskeleton morphology and de-activation of RhoA GTPase. Moreover, a siginificant reduction was observed in the self-renewal of breast cancer stem cells, while severe morphological alterations were observed in cells grown in 3D culture conditions.In conclusion, the present doctorate’s thesis studied and characterized three inhibitors of hyaluronan biosynthesis: 4-MU (in relation to the ER status of the cells), salicylate (the active compound of the classic non-steroid anti-inflammatory drug aspirin) and the new synthetic compound SMD1736. The reduction of hyaluronan levels by all three compounds was accompanied by inhibition of breast cancer cell aggressive properties, pinpointing the significance of hyaluronan system targeting in breast cancer. All three compounds displayed significant effects that make them very promising means for the development of novel matrix-based therapeutic approaches for complex pathologies characterized by extended biosynthesis and accumulation of hyaluronan, such as breast cancer.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Karalis, Theodoros
  • Καραλής, Θεόδωρος

Subjects

dc:subject × 18

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/48991

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Karalis, Theodoros; Καραλής, Θεόδωρος. Ρύθμιση βιοσύνθεσης υαλουρονικού οξέος σε κυτταρικά μοντέλα καρκίνου του μαστού. University of Patras, 2021. http://hdl.handle.net/10442/hedi/48991